RGEN · Nasdaq · CIK 0000730272

REPLIGEN CORP

REPLIGEN CORP’s most recent SEC filing in our snapshot is a Form 8-K filed on Oct 27, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $738.3M and net income of $48.9M, according to its XBRL data on EDGAR. Its EDGAR record lists 42 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$738.3M
Net income, FY2025
$48.9M
Form 4 filings on record, past 12 months
42

Company overview

Legal name (as filed)
REPLIGEN CORP
Ticker
RGEN
SEC Central Index Key (CIK)
0000730272
Business address
WALTHAM, MA
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#846 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from REPLIGEN CORP’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$670.5MFY2021$801.5MFY2022$632.4MFY2023$634.4MFY2024$738.3MFY2025
Net income
$128.3MFY2021$186.0MFY2022$35.6MFY2023-$25.5MFY2024$48.9MFY2025
RGEN annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue$670.5M$801.5M$632.4M$634.4M$738.3M
Net income$128.3M$186.0M$35.6M-$25.5M$48.9M
Diluted EPS$2.24$3.24$0.63-$0.46$0.86
Total assets$2.4B$2.5B$2.8B$2.8B$2.9B
Cash and equivalents$603.8M$523.5M$751.3M$757.4M$566.0M

XBRL tags used: revenue = RevenueFromContractWithCustomerIncludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

RGEN latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Feb 26, 202610-KAnnual report· period Dec 31, 2025Document · Index
Jul 29, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Oct 27, 20268-KResults of operations· period Oct 27, 2026Document · Index
Apr 2, 2026DEF 14ADefinitive proxy statement· period May 14, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about REPLIGEN CORP, by form type:

4 ×12144 ×8425 ×68-K ×6SCHEDULE 13G/A ×2EFFECT ×1424B3 ×1S-4/A ×1S-4 ×1SCHEDULE 13G ×110-Q ×1
RGEN recent filings
FiledFormWhat it isOriginal
Oct 27, 20268-KResults of operations· period Oct 27, 2026Document · Index
Oct 8, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 6, 2026Document · Index
Oct 7, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Oct 6, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 5, 2026Document · Index
Oct 6, 20268-KAcquisition or disposition completed; Regulation FD disclosure· period Oct 6, 2026Document · Index
Oct 5, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 5, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 5, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 2, 2026Document · Index
Sep 30, 2026425425Document · Index
Sep 28, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 25, 2026Document · Index
Sep 25, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 24, 2026Document · Index
Sep 24, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 22, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 21, 2026Document · Index
Sep 21, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 15, 20268-KDirector or officer change· period Sep 10, 2026Document · Index
Sep 8, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 3, 2026Document · Index
Sep 8, 2026425425Document · Index
Sep 8, 20268-KOther events· period Sep 3, 2026Document · Index
Sep 4, 2026EFFECTEFFECTDocument · Index
Sep 4, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 4, 2026424B3424B3Document · Index
Sep 4, 2026S-4/ARegistration statement for business combinationsDocument · Index
Sep 2, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 5, 2026Document · Index
Aug 25, 2026S-4Registration statement for business combinationsDocument · Index
Aug 21, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 20, 2026Document · Index
Aug 20, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 4, 2026425425Document · Index
Jul 31, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Jul 29, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Jul 28, 20268-KResults of operations· period Jul 28, 2026Document · Index
Jul 24, 2026425425Document · Index
Jul 22, 2026425425Document · Index
Jul 22, 2026425425Document · Index
Jul 22, 20268-KMaterial agreement; Results of operations; Regulation FD disclosure; Other events· period Jul 21, 2026Document · Index
Jul 17, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 16, 2026Document · Index
Jul 16, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 26, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 25, 2026Document · Index
Jun 25, 2026144Notice of proposed sale of securitiesDocument · Index
May 18, 20264Statement of changes in beneficial ownership (insider trade)· period May 14, 2026Document · Index

Insider filing activity

42 Form 4 filings appear in REPLIGEN CORP’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Biological Products, (No Diagnostic Substances)

All 61 companies in Biological Products, (No Diagnostic Substances)· Companies headquartered in Massachusetts

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0000730272 and XBRL company facts. REPLIGEN CORP on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.